Despite scoring on the primary and secondary endpoints in its phase III topline readout, Calliditas’ shares have suffered and are now trading in Bear territory. In our view, the stock market fails to recognise Calliditas’ emerging transformation into a commercial-stage biopharma. Following a review of this exciting case, we are even raising our Base Case to SEK 280 (250) per share.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se